Yohimbe Pausinystalia yohimbe
Also called: johimbi, Corynanthe johimbe, yohimbine
An evergreen tree native to central and western Africa. Its bark contains yohimbine and has traditionally been used as an aphrodisiac. Bark products are sold as supplements; human research is sparse and documented risks are serious.
- Category
- Botanical
- Part used
- Bark
- Strongest evidence
- D Lab or animal only
- Reviewed
- 2026-10-28
Class 4 Animal studies only. No human trial of yohimbe bark was found; bark studies found were in mice and rats. Human trials tested yohimbine hydrochloride, the purified alkaloid (two 1997 trials opened; 7 yohimbine trials pooled in 1998); NCCIH notes a prescription medicine contains yohimbine. This class does not count them. [3]
Fact-checked 2026-10-28 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
DBlood sugar and weight1 topic
DHormones and reproduction1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Erectile dysfunction (yohimbe bark supplements) | D | NCCIH states there is not enough research to know whether yohimbe supplements help; they may not work like the prescription medicine that contains yohimbine. [1] |
| Athletic performance and obesity | D | NCCIH states there is not enough research to determine whether yohimbe helps with athletic performance or obesity. [1] |
Main constituents: Indole alkaloids, chiefly yohimbine [2]
Safety and side effects
- Liver (NIH LiverTox)Score EABCDEA: well known causeE: unlikely cause
LiverTox likelihood score E (unlikely cause of clinically apparent liver injury), chapter updated 2020-04-05.
Details and sources - Pregnancy and breastfeedingNCCIH: it might be unsafe to use yohimbe orally during pregnancy or while breastfeeding.
2 statements in the profile.
Details and sources - Interactions with medicines5 listed
Monoamine oxidase inhibitors (MAOIs); CYP2D6 substrates; Bupropion; Antihypertensives, antianxiety agents, antidepressants, opioids …
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Yohimbine has been associated with irregular heartbeat, blood pressure problems, heart attacks and seizures. [1]
- Over 7 years of California Poison Control System calls, yohimbe callers reported stomach problems, rapid heartbeat, anxiety and high blood pressure, and were generally more likely to need medical care than other callers. [1]
- Other reported adverse effects: nervousness, nausea, dizziness, palpitations, insomnia, urinary frequency, diarrhea, manic symptoms and cardiotoxicity. [2]
- Listed contraindications: heart and blood vessel disease, high blood pressure, liver or kidney disorders, psychiatric conditions such as PTSD, bipolar disorder and schizophrenia, enlarged prostate, and pregnancy. [2]
- Oral use may be unsafe during pregnancy or while breastfeeding. [1]
Interactions
| With | What happens |
|---|---|
| MAO inhibitors and tricyclic antidepressants | Do not use yohimbe with these antidepressants; they can interact. [1] |
| Other antidepressants | Yohimbine may augment side effects. [2] |
| Bupropion | Taking yohimbe products together with bupropion resulted in toxic effects. [2] |
| Blood pressure medicines (antihypertensives) | Yohimbine may diminish their effects. [2] |
| Anti-anxiety medicines | Yohimbine may reduce their therapeutic effects. [2] |
| Opioids; CYP2D6 substrate drugs | Yohimbine may induce opioid withdrawal and anxiety symptoms, and inhibits CYP2D6, which may affect levels of drugs metabolized by it. [2] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- A 2015 analysis of 49 US brands found most did not state yohimbine content, amounts varied widely, and some yohimbine was synthetic or from highly processed extracts; 18% of labels gave no side-effect information, and only 2 of 49 gave both an accurate yohimbine amount and side-effect information. [1]
Regulatory status
- US: marketing an over-the-counter yohimbine product for erectile dysfunction without FDA approval is illegal. Yohimbe bark is sold as a dietary supplement; supplements are not FDA-approved before sale. [1]
- Elsewhere: because of inaccurate labeling and the risk of serious side effects, yohimbe supplements have been restricted or banned in many countries. [1]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming yohimbe (Pausinystalia johimbe) or yohimbine was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P3]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- LiverTox likelihood score E (unlikely cause of clinically apparent liver injury), chapter updated 2020-04-05. LiverTox notes occasional severe adverse events and that overdose can cause hypotension, tachycardia, seizures, paralysis and coma, with deaths described. [P1]
Interactions with medicines
- Monoamine oxidase inhibitors (MAOIs): NCCIH: do not use yohimbe with MAOI antidepressants. [P6]
- CYP2D6 substrates: Yohimbine inhibits CYP2D6 and may alter the metabolism of these drugs. [P7]
- Bupropion: Co-ingestion resulted in toxic effects. [P7]
- Antihypertensives, antianxiety agents, antidepressants, opioids: May lessen the effects of blood pressure and antianxiety medicines, increase antidepressant side effects, and cause withdrawal and anxiety symptoms with opioids. [P7]
- Decongestants, diet aids, phenylpropanolamine: MSK warns against combining yohimbe with these products. [P7]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- Of 49 US supplement brands labeled as containing yohimbe or yohimbine (UHPLC with PDA and QTOF-MS), yohimbine per serving ranged from none detected to 12.1 mg; 39% (19/49) contained no rauwolscine or corynanthine, suggesting highly processed extract or synthetic yohimbine; only 22% stated a yohimbine quantity, and most of those were inaccurate (23% to 147% of label). [P2]
- UHPLC fingerprinting of 18 yohimbe supplements found wide variability in fingerprints and yohimbine content; for most, yohimbine content was not consistent with label claims. [P8]
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination of each component that is a dietary ingredient — Required by 21 CFR 111.75(a)(1)(i) for every dietary-ingredient component; an exemption may be requested by petition under 21 CFR 10.30. [P9]
- Yohimbine quantification plus rauwolscine and corynanthine profile (UHPLC-UV/MS against reference standards) — Label yohimbine content is often inaccurate, and absence of the co-occurring bark alkaloids suggests highly processed or synthetic yohimbine. [P2]
- Chromatographic fingerprint separating corynanthine from yohimbine — Developed for yohimbe bark and supplements, in which fingerprints and yohimbine content varied widely. [P8]
Supply and conservation
Absorption in people
- After single 10 mg oral and intravenous doses of yohimbine hydrochloride in 7 healthy young men, elimination was rapid (half-life 0.58 h oral, 0.68 h IV) and oral bioavailability varied from 7% to 87% (mean 33%), reflecting incomplete absorption or hepatic first-pass effect. [P11]
- After a single 10 mg oral dose in 8 young men, absorption half-time was 0.17 ± 0.11 h and elimination half-life 0.60 ± 0.26 h; virtually no yohimbine appeared in urine (0.35% of dose), indicating elimination mainly by metabolism. [P12]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Sources for this profile
- NIH LiverTox (NIDDK). Yohimbine (Last Update: 2020-04-05), 2020-04-05. ncbi.nlm.nih.gov
- Cohen PA, et al. Pharmaceutical quantities of yohimbine found in dietary supplements in the USA. Drug Test Anal 2016;8(3-4):357-69 (PMID 26391406), 2016-03. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. Agents Classified by the IARC Monographs: List of Classifications (accessed 2026-10-29), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program (NIEHS). Technical Reports list (accessed 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- NCCIH. Yohimbe: Usefulness and Safety (Last Updated: May 2025), 2025-05. nccih.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Yohimbe (last updated December 17, 2021), 2021-12-17. mskcc.org
- Sun J, Chen P. Chromatographic fingerprint analysis of yohimbe bark and related dietary supplements using UHPLC/UV/MS. J Pharm Biomed Anal 2012;61:142-9 (PMID 22221902), 2012-03-05. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- GBIF species API: IUCN Red List category for Corynanthe johimbe K.Schum. (Pausinystalia johimbe), 2026-10-29. api.gbif.org
- Guthrie SK, et al. Yohimbine bioavailability in humans. Eur J Clin Pharmacol 1990;39(4):409-11 (PMID 2076728), 1990. pubmed.ncbi.nlm.nih.gov
- Owen JA, et al. The pharmacokinetics of yohimbine in man. Eur J Clin Pharmacol 1987;32(6):577-82 (PMID 3653227), 1987. pubmed.ncbi.nlm.nih.gov
Sources
- NCCIH. Yohimbe: Usefulness and Safety (last updated May 2025), 2025-05. nccih.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Yohimbe (last updated December 17, 2021), 2021-12-17. mskcc.org
- Al-Majed AA, et al. Reproductive, cytological and biochemical toxicity of Yohimbe in male Swiss albino mice. Asian J Androl 2006;8(4):469-76 (PMID 16763724), 2006-07. pubmed.ncbi.nlm.nih.gov
- Ajayi AA, et al. Endothelin-like action of Pausinystalia yohimbe aqueous extract on vascular and renal regional hemodynamics in Sprague Dawley rats. Methods Find Exp Clin Pharmacol 2003;25(10):817-22 (PMID 14735230), 2003-12. pubmed.ncbi.nlm.nih.gov
- Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 1998;159(2):433-6 (PMID 9649257), 1998-02. pubmed.ncbi.nlm.nih.gov
- Kunelius P, et al. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. Urology 1997;49(3):441-4 (PMID 9123711), 1997-03. pubmed.ncbi.nlm.nih.gov
- Vogt HJ, et al. Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Int J Impot Res 1997;9(3):155-61 (PMID 9315493), 1997-09. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.